Job title: Vice President, Pharmaceutical Development
Claire M. Gelfman, Ph.D. serves as Adverum’s vice president, pharmaceutical development. Previously, she was the senior director of scientific services at Ora, Inc., an ophthalmic contract research organization (CRO) where she designed and implemented preclinical translational strategies and integrated them into the clinical development process. Prior positions included director of ophthalmology research at Lpath Inc evaluating humanized monoclonal antibodies directed against bioactive lipids, as well as principal scientist at Lexicon Pharmaceuticals where she directed early drug discovery efforts using gene therapy, cellular, and biochemical approaches, and focused on in vivo pharmacology studies in the areas of ocular inflammation and retinal degeneration. Her experience covers more than 20 years in ophthalmic drug discovery and development, spanning biopharma and the CRO industry. Dr. Gelfman holds a B.A. in Biology from Washington University in St. Louis, and a Ph.D. in Biochemistry from The University of Texas at Austin.
Intravitreal Delivery of Gene Therapy Vectors to Treat Retinal Disease 11:30 am
• Discussing progress of intravitreal delivery of gene therapies as a less invasive procedure for patients • Understanding challenges of making intravitreal delivery commonplace for gene therapies • Reviewing ADVM-022: an intravitreal gene therapy product for patients with nAMDRead more
day: Day One
PANEL DISCUSSION: Evaluating Advantages and Disadvantages of Different Administration Routes 12:30 pm
Delivery is a hot topic in the ophthalmology space. It’s clear that a myriad of factors influence which administration route is chosen, and it’s vital to choose the right one for your indication, taking into account what is best not just for effectiveness of the therapy, but for the patient. This panel discussion will bring…Read more
day: Day One